Augtyro (repotrectinib) — Medica
Non-small cell lung cancer (ROS1-positive)
Initial criteria
- Patient is age ≥ 18 years
- Patient has locally advanced or metastatic disease
- Patient has ROS1-positive non-small cell lung cancer
- The mutation was detected by an approved test
Approval duration
1 year